Linnaeus Therapeutics, Inc.

Privately held: no public share price · United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2/3
GPER (G protein-coupled estrogen receptor)Small molecule
Non-Small Cell Lung CancerMelanoma

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
February 2029 (1)
LNS8801Phase 2/3Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma, Unresectable Melanoma
Est. primary completion 2029-02 · NCT06624644 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.